EGR1

EGR1 Full Name

early growth response 1

EGR1 Introduction

Early Growth Response 1 (EGR1) is an immediate-early response transcription factor that rapidly translates extracellular signals into coordinated changes in gene expression, making it one of the most important regulators of cellular adaptation to environmental stimuli. Encoded by the EGR1 gene, this highly conserved C2H2 zinc-finger DNA-binding protein is expressed in response to diverse physiological and pathological signals, including growth factors, cytokines, DNA damage, hypoxia, oxidative stress, mechanical stimulation, and neuronal activity. Unlike many transcription factors that require sustained activation, EGR1 is induced within minutes following stimulation, enabling cells to rapidly initiate appropriate transcriptional programs. Current evidence indicates that the human EGR1 gene contains two exons separated by a single intron and lacks alternative splice variants, reflecting its evolutionarily conserved structure. As a transcriptional regulator, EGR1 binds specific DNA response elements within promoter regions and can either activate or repress downstream target genes depending on cellular context, chromatin accessibility, interacting cofactors, and upstream signaling pathways. This remarkable regulatory flexibility has established EGR1 as a central molecular switch that integrates transient extracellular cues into long-lasting biological responses, making it an increasingly valuable target for mechanistic studies, biomarker discovery, and therapeutic research.

EGR1 participates in a wide range of biological processes that are essential for normal development and tissue homeostasis. It functions downstream of multiple signaling cascades, including the PI3K/AKT, Ras/ERK, MAPK/ERK, p38 MAPK, and JNK pathways, where it regulates genes involved in cell proliferation, differentiation, apoptosis, migration, angiogenesis, inflammation, extracellular matrix remodeling, endocrine regulation, and wound healing. In the nervous system, EGR1 is a critical activity-dependent transcription factor that supports synaptic plasticity, neuronal differentiation, learning, and long-term memory formation. Its expression also contributes to vascular remodeling through the regulation of angiogenic mediators such as VEGF, hypoxia-inducible factors, and thrombospondin-1. The transcriptional activity of EGR1 is further fine-tuned through interactions with regulatory proteins including NAB1, NAB2, C/EBPβ, JUN, and ERK1/2, allowing highly context-specific gene regulation. More recent studies have demonstrated that EGR1 directly activates RRN3, thereby promoting RNA polymerase I-mediated ribosomal RNA transcription and ribosome biogenesis, revealing an additional mechanism by which EGR1 supports cellular growth and metabolic activity. Collectively, these diverse functions position EGR1 as a master transcriptional regulator capable of coordinating multiple signaling networks into integrated cellular responses.

Dysregulation of EGR1 has been implicated in numerous human diseases, with its biological effects varying according to tissue type, disease stage, and cellular microenvironment. In cancer, EGR1 displays a well-recognized dual role, functioning either as a tumor suppressor or as an oncogenic factor depending on the molecular context. It regulates key processes associated with tumor initiation and progression, including epithelial-mesenchymal transition (EMT), cell-cycle progression through Cyclin D1, Cyclin D2, and CDK4, extracellular matrix degradation via MMP1 and MMP9, angiogenesis, invasion, metastasis, and apoptosis. Recent evidence further suggests that EGR1 promotes tumor growth in certain malignancies by activating RRN3 expression and enhancing RNA polymerase I-dependent ribosomal RNA synthesis. Beyond oncology, EGR1 has been linked to neurological disorders because of its essential role in neuronal plasticity and cognitive function, while its regulation of inflammatory signaling and vascular remodeling also contributes to cardiovascular and inflammatory diseases. Increasing attention has also focused on the involvement of EGR1 in host responses to viral infections. Multiple viruses, including Venezuelan equine encephalitis virus (VEEV), Kaposi's sarcoma-associated herpesvirus (KSHV), herpes simplex virus type 1 (HSV-1), human immunodeficiency virus (HIV), and Epstein-Barr virus (EBV), can induce EGR1 expression, allowing the transcription factor to influence antiviral immunity, inflammatory responses, viral replication, and host-cell survival. As a convergence point for multiple signaling pathways with broad physiological and pathological functions, EGR1 continues to be recognized as a promising biomarker, therapeutic target, and mechanistic regulator across oncology, neuroscience, immunology, infectious diseases, and translational biomedical research.

Alternate Names for EGR1

EGR1; early growth response 1; TIS8; AT225; G0S30; NGFI-A; ZNF225; KROX-24; ZIF-268; early growth response protein 1; EGR-1; zinc finger protein 225; transcription factor ETR103; transcription factor Zif268; zinc finger protein Krox-24; nerve growth factor-induced protein A;

• 1.Na IH, Cheon YP. Genetic Anatomy and Ontogenetic Roles of Early Growth Response 1 (Egr1) in Human and Mouse. Dev Reprod. 2026, 30(1):1-23.
  2.Guo R, et al.; Multifaceted regulatory mechanisms of the EGR family in tumours and prospects for therapeutic applications (Review). Int J Mol Med. 2025, 56(1):113.